Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Arteriosclerosis Obliterans D001162 8 associated lipids
Carcinoma, Embryonal D018236 8 associated lipids
Cholecystitis D002764 8 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Leukopenia D007970 9 associated lipids
Salmonella Infections, Animal D012481 9 associated lipids
Immune Complex Diseases D007105 9 associated lipids
Staphylococcal Skin Infections D013207 9 associated lipids
Carbon Monoxide Poisoning D002249 9 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Renal Insufficiency, Chronic D051436 9 associated lipids
Fetal Growth Retardation D005317 9 associated lipids
Respiratory Syncytial Virus Infections D018357 10 associated lipids
Pancreatitis D010195 10 associated lipids
Central Nervous System Diseases D002493 10 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Rhinitis D012220 10 associated lipids
Pregnancy Complications, Cardiovascular D011249 11 associated lipids
Shock, Septic D012772 11 associated lipids
Venous Thrombosis D020246 11 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Infertility, Male D007248 11 associated lipids
Migraine Disorders D008881 11 associated lipids
Shock D012769 11 associated lipids
Meningioma D008579 11 associated lipids
Pregnancy Complications, Hematologic D011250 11 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Death, Sudden D003645 12 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Blood Platelet Disorders D001791 12 associated lipids
Amnesia D000647 12 associated lipids
Hypertension, Portal D006975 12 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Fetal Weight D020567 12 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Heart Arrest D006323 13 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Hypercalcemia D006934 13 associated lipids
Polycythemia Vera D011087 13 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Stomatitis D013280 14 associated lipids
Angina, Unstable D000789 14 associated lipids
Hemorrhage D006470 15 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Respiratory Distress Syndrome, Adult D012128 15 associated lipids
Neutropenia D009503 15 associated lipids
Thrombocytopenia D013921 15 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Encephalitis D004660 15 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Moon DG et al. Platelet modulation of neutrophil superoxide anion production. 1990 Thromb. Haemost. pmid:2160133
Tranquille N and Emeis JJ The role of cyclic nucleotides in the release of tissue-type plasminogen activator and von Willebrand factor. 1993 Thromb. Haemost. pmid:8097063
Iyú D et al. The role of prostanoid receptors in mediating the effects of PGE3 on human platelet function. 2012 Thromb. Haemost. pmid:22318645
Wal F et al. PAF-acether may not mediate the third pathway of platelet aggregation since self-desensitization reduces the effects of low thrombin but enhances those of convulxin. 1985 Thromb. Haemost. pmid:3992525
Smith SV and Brinkhous KM Inventory of exogenous platelet-aggregating agent derived from venoms. 1991 Thromb. Haemost. pmid:1771620
Hermán F et al. Decreased sensitivity of platelets to platelet-activating factor in migraine patients during the headache-free interval. 1989 Thromb. Haemost. pmid:2814933
Hornby EJ and Perry CR 1-O-hexadecyl-2-acetyl-sn-3-glycerophosphorylcholine (PAF): some effects on the aggregation of human platelets by thrombin or collagen. 1983 Thromb. Haemost. pmid:6636035
Handley DA et al. Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemoconcentration in the guinea pig. 1985 Thromb. Haemost. pmid:4089809
Cargill DI et al. Aggregation, release and desensitization induced in platelets from five species by platelet activating factor (PAF). 1983 Thromb. Haemost. pmid:6879508
Chou KJ et al. Platelet hyperreactivity in hemodialysis patients with frequently occluded vascular access. 2004 Thromb. Haemost. pmid:15351860
Handley DA et al. Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441. 1986 Thromb. Haemost. pmid:3775689
Ou MC et al. Potential etiologic role of PAF in two major septic complications; disseminated intravascular coagulation and multiple organ failure. 1994 Thromb. Res. pmid:8191415
Le Blanc K et al. Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. 1998 Thromb. Res. pmid:9772010
Eche N et al. Platelet aggregating and procoagulant activities of cultured human breast cancer cells (FAM). 1986 Thromb. Res. pmid:3726808
Powling MJ and Hardisty RM Differential effects of 12-O-tetradecanoylphorbol 13-acetate on platelet responses to various agonists in the presence and absence of extracellular Ca2+. 1986 Thromb. Res. pmid:3787566
Siffert W et al. Inhibition of platelet aggregation by amiloride. 1986 Thromb. Res. pmid:3787567
Alam I et al. Human and rabbit platelets form platelet-activating factor in response to calcium ionophore. 1983 Thromb. Res. pmid:6407140
Bochkov VN et al. LDL- and agonist-induced Ca(2+)-mobilization in platelets of healthy subjects and in patients with familial hyperlipoproteinemia type II. 1991 Thromb. Res. pmid:2063348
Bush LR and Smith SG Antagonism of U46619-induced aggregation of human and canine platelets by four TXA2 receptor antagonists. 1986 Thromb. Res. pmid:2948294
Filep JG et al. C-reactive protein inhibits binding of platelet-activating factor to human platelets. 1991 Thromb. Res. pmid:2063349
Slattery CW and Beaumont DO Sheep platelets as a model for human platelets: evidence for specific PAF (platelet activating factor) receptors. 1989 Thromb. Res. pmid:2554526
Belch JJ et al. Whole blood white cell aggregation: a novel technique. 1987 Thromb. Res. pmid:2448894
Ostermann G et al. Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor. 1983 Thromb. Res. pmid:6408754
Liu X et al. Ginkgolide B inhibits platelet release by blocking Syk and p38 MAPK phosphorylation in thrombin-stimulated platelets. 2014 Thromb. Res. pmid:25223809
Nguyên P et al. Mechanisms of the platelet aggregation induced by activated neutrophils and inhibitory effect of specific PAF receptor antagonists. 1995 Thromb. Res. pmid:7778064
Vargaftig BB et al. Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. 1982 Thromb. Res. pmid:7164036
Namm DH and High JA Thrombin-induced formation of a polar lipid material within platelets that possesses platelet-activating activity. 1980 Thromb. Res. pmid:7209881
Hanss M and Dechavanne M 48740 RP, an antagonist of PAF, does not affect human plasma fibrinolysis before and after venous occlusion. 1988 Thromb. Res. pmid:3126559
Okamoto M et al. Platelet activating factor (PAF) involvement in endotoxin-induced thrombocytopenia in rabbits: studies with FR-900452, a specific inhibitor of PAF. 1986 Thromb. Res. pmid:3754990
Sturk A et al. Synergistic effects of platelet-activating factor and other platelet agonists in human platelet aggregation and release: the role of ADP and products of the cyclooxygenase pathway. 1985 Thromb. Res. pmid:2934863
Namm DH et al. Species specificity of the platelet responses to 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine. 1982 Thromb. Res. pmid:7071810
Juhan-Vague I et al. Possible participation of adenosine 5'-diphosphate, arachidonic acid and paf-acether in the platelet pro-aggregating effect of uncontrolled insulin-dependent diabetic erythrocytes in vitro. 1985 Thromb. Res. pmid:3923649
Violi F et al. Inhibition of cyclooxygenase-independent platelet aggregation by sodium salicylate. 1989 Thromb. Res. pmid:2506658
Shukla SD et al. Hypersensitivity of diabetic human platelets to platelet activating factor. 1992 Thromb. Res. pmid:1329254
Tsien WH et al. Variable responses of human platelets to synthetic platelet activating factor and their modification by epinephrine. 1982 Thromb. Res. pmid:7164038
Kurose I et al. Involvement of superoxide anion and platelet-activating factor in increased tissue-type plasminogen activator during rat gastric microvascular damages. 1991 Thromb. Res. pmid:1650966
Westwick J et al. Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. 1986 Thromb. Res. pmid:3715810
Valone FH Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers. 1987 Thromb. Res. pmid:3590086
Tokumura A et al. Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists. 1987 Thromb. Res. pmid:3590110
Brown JE and Thuy LP The binding of bovine platelet aggregating factor to human platelets. 1981 Apr 1-15 Thromb. Res. pmid:7292446
Kloprogge E et al. Properties of PAF-acether-induced platelet aggregation and secretion. Studies in gel-filtered human platelets. 1983 Thromb. Res. pmid:6222507
Ishii H et al. Thiolprotease inhibitor, EST, can inhibit thrombin-induced platelet activation. 1990 Thromb. Res. pmid:2382255
Wade PJ et al. Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets. 1986 Thromb. Res. pmid:3961730
Karlsson H et al. Heparin ameliorates pulmonary hypertension induced by platelet-activating factor in pigs. 1998 Thromb. Res. pmid:9694244
Hofmann B et al. Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets. 1988 Thromb. Res. pmid:3381200
Cox CP and Wood KL Selective antagonism of platelet-activating factor (PAF)-induced aggregation and secretion in washed rabbit platelets by CV-3988, L-652731, triazolam and alprazolam. 1987 Thromb. Res. pmid:3629553
Catalán RE et al. Dissociation between secretion and protein phosphorylation in agonist-stimulated platelets; action of PCA-4230, a new antithrombotic drug. 1994 Thromb. Res. pmid:7974386
Ostermann G et al. Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. 1987 Thromb. Res. pmid:3629555
Davis RB and Johnson MF Effects of bacterial endotoxin and platelet activating factor (PAF) on human platelet aggregation in native whole blood. 1986 Thromb. Res. pmid:3544327
Nishizawa EE and Della-Coletta AA The formation of a thrombin-like material (TLM) following stimulation of leukocytes. 1984 Thromb. Res. pmid:6484896
Glusa E et al. Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation. 1989 Thromb. Res. pmid:2528843
Stahl GL et al. Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock. 1989 Thromb. Res. pmid:2718150
Valone FH Platelet-activating factor binding and metabolism during human platelet aggregation. 1988 Thromb. Res. pmid:3400077
Sloan IG and Firkin BG Impaired fibrinolysis in patients with thrombotic or haemostatic defects. 1989 Thromb. Res. pmid:2814943
Skeaff CM and Holub BJ The effect of fish oil consumption on platelet aggregation responses in washed human platelet suspensions. 1988 Thromb. Res. pmid:3187952
Griffin KJ and Levy JV The thieno-triazolodiazepine WEB 2086 inhibits platelet aggregation and ATP release from porcine platelets induced by platelet activating factor (PAF). 1988 Thromb. Res. pmid:3187959
Ostermann G et al. Cooperative effects of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) and exogenous arachidonic acid in stimulation of human blood platelets. 1984 Thromb. Res. pmid:6710440
Petty AC and Scrutton MC Platelet aggregation in whole blood: is the response to adrenaline, 5-hydroxytryptamine and PAF a direct consequence of stimulation by these agonists? 1989 Thromb. Res. pmid:2749609
Lalau Keraly C et al. Inhibition by ticlopidine of Paf-acether-induced in vitro aggregation of rabbit and human platelets. 1984 Thromb. Res. pmid:6740569
Beaumont DO et al. Measuring platelet function with platelet shape change, an early event in aggregation. 1989 Thromb. Res. pmid:2646752
Janero DR et al. Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet. 1988 Thromb. Res. pmid:3413730
Moon DG et al. Platelet activating factor and sheep platelets: a sensitive new bioassay. 1990 Thromb. Res. pmid:2326773
Violi F et al. Human platelet aggregation by PAF and thromboxane production. 1987 Thromb. Res. pmid:3424290
Benveniste J et al. Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. 1982 Thromb. Res. pmid:6803388
Seth P et al. Effect of platelet activating factor antagonists in different models of thrombosis. 1994 Thromb. Res. pmid:7900097
Bernat A and Herbert JM Effect of various drugs on adriamycin-enhanced venous thrombosis in the rat: importance of PAF. 1994 Thromb. Res. pmid:8073411
Klöcking HP et al. Release of tissue-type plasminogen activator by platelet-activating factor. 1985 Thromb. Res. pmid:4040278
Cox CP Effects of CV-3988, an antagonist of platelet-activating factor (PAF), on washed rabbit platelets. 1986 Thromb. Res. pmid:2421432
Croft KD and Beilin LJ Platelet and neutrophil function and eicosanoid release in a subject with abetalipoproteinaemia. 1993 Thromb. Res. pmid:8385810
Vrzheshch PV et al. Cell response kinetics: the phenomenon of supercooperativity in aggregation of human platelets. 1992 Thromb. Res. pmid:1523610
Teng CM et al. Antiplatelet actions of some coumarin compounds isolated from plant sources. 1992 Thromb. Res. pmid:1523611
Chlopicki S et al. Obligatory role of lipid mediators in platelet-neutrophil adhesion. 2003 Thromb. Res. pmid:14592550
Valone FH and Johnson B Decay of the activating signal after platelet stimulation with 1-0-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine: changes in calcium permeability. 1985 Thromb. Res. pmid:4082115
Kohayakawa M and Inoue K Augmentation of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF)-induced human platelet activation by C-reactive protein. 1986 Thromb. Res. pmid:3083530
Ostermann G et al. The role of lipoproteins in the degradation of platelet-activating factor. 1986 Thromb. Res. pmid:3798402
Battistini B et al. Endothelin-1 does not affect human platelet aggregation in whole blood and platelet rich plasma. 1990 Thromb. Res. pmid:2278035
Tencé M et al. Ether-phospholipid composition in neutrophils and platelets. 1985 Thromb. Res. pmid:4024039
Hadváry P and Baumgartner HR Activation of human and rabbit blood platelets by synthetic structural analogs of platelet activating factor. 1983 Thromb. Res. pmid:6868019
Tan EL and Snyder F Metabolism of platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by capillary endothelial cells isolated from rat epididymal adipose tissue. 1985 Thromb. Res. pmid:4024051
Hayashi M et al. Detection of platelet-activating factor in exudates of rats with phorbol myristate acetate-induced pleurisy. 1987 Thromb. Res. pmid:3433255
Ding YA et al. Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound. 1995 Thromb. Res. pmid:7740521
Bussolino F et al. Intravascular release of platelet activating factor in children with sepsis. 1987 Thromb. Res. pmid:3441909
Suzuki K et al. The influence of 2-mercaptoethanol on von Willebrand factor and bovine platelet aggregating factor. 1980 Feb 1-15 Thromb. Res. pmid:6966083
Küster LJ and Frölich JC PAF-induced platelet aggregation and TXB2 formation. 1989 Thromb. Res. pmid:2922704
Ostermann G et al. Stimulation and desensitization of human and rabbit platelets by 1-O-hexadecyl-2-O-methyl-rac-glycero-3-phosphocholine and analogues. 1986 Thromb. Res. pmid:3764811
Ishii H et al. A platelet aggregating substance contained in xanthine oxidase preparation from cow's milk. 1982 Thromb. Res. pmid:6897588
Ostermann G et al. The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patients. 1988 Thromb. Res. pmid:3232123
Avdonin PV et al. Blocking of the receptor-stimulated calcium entry into human platelets by verapamil and nicardipine. 1988 Thromb. Res. pmid:3232128
Neiman J et al. Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. 1989 Thromb. Res. pmid:2617478
Pfliegler G et al. Sodium fluoride induced activation of phospholipase C in intact human platelets does not depend on ADP, PAF or arachidonate products. 1993 Thromb. Res. pmid:8503122
Altman R et al. Why single daily dose of aspirin may not prevent platelet aggregation. 1988 Thromb. Res. pmid:3140408
Avdonin PV et al. Evidence for the receptor-operated calcium channels in human platelet plasma membrane. 1987 Thromb. Res. pmid:2438805
Lukaszyk A et al. Does acute experimental pancreatitis affect blood platelet function? 1989 Thromb. Res. pmid:2524119
Lecompte T et al. Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP. 1990 Thromb. Res. pmid:2117306
McGowan EB and Detwiler TC Characterization of the thrombin-induced desensitization of platelet activation by thrombin. 1983 Thromb. Res. pmid:6356458
Mabilat-Pragnon C et al. Urokinase localization and activity in isolated eosinophils. 1997 Thromb. Res. pmid:9526961
Kinlough-Rathbone RL et al. Effects of cathepsin G pretreatment of platelets on their subsequent responses to aggregating agents. 1999 Thromb. Res. pmid:10527409
Csáki C et al. Role of platelet-activating factor in the development of endothelial dysfunction in hemorrhagic hypotension and retransfusion. 1992 Thromb. Res. pmid:1412179
May JA et al. Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. 1997 Thromb. Res. pmid:9361371
Lian EC et al. Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. 1984 Thromb. Res. pmid:6420930